CEO Cokey Nguyen expressed confidence in resolving the issue, expecting resubmission and potential approval within six months of addressing the manufacturing compliance concerns.
Atara Biotherapeutics ATRA is a nimble allogeneic T cell immunotherapy company with several near-term catalysts. This Zacks Rank #2 (Buy) company boasts a pipeline of differentiated therapies across a...
Jill Henrich, the EVP of $ATRA ($ATRA), sold 1,000 shares of the company on 11-18-2024. We received data on the trade from a recent SEC filing. This was a sale of approximately 4.9% of their shares. Following...
Atara Biotherapeutics: Q3 Earnings Snapshot
Atara Biotherapeutics: Q2 Earnings Snapshot
This tiny stock could soar more than 400%, according to Wall Street.
Atara Biotherapeutics: Q1 Earnings Snapshot
Atara Biotherapeutics: Q4 Earnings Snapshot
Atara Biotherapeutics: Q3 Earnings Snapshot
Atara Biotherapeutics: Q2 Earnings Snapshot